Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma (Q46664276)

24 December 2017

title

Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma (English)

1 reference

24 December 2017

1 reference

1

Reinhard Dummer

1 reference

24 December 2017

author name string

Christoph Rochlitz

2

1 reference

24 December 2017

Thierry Velu

3

1 reference

24 December 2017

Bruce Acres

4

1 reference

24 December 2017

Jean-Marc Limacher

5

1 reference

24 December 2017

Pascal Bleuzen

6

1 reference

24 December 2017

Gisèle Lacoste

7

1 reference

24 December 2017

Philippe Slos

8

1 reference

24 December 2017

Pedro Romero

9

1 reference

24 December 2017

Mirjana Urosevic

10

1 reference

24 December 2017

publication date

18 March 2008

1 reference

24 December 2017

published in

Molecular Therapy

1 reference

24 December 2017

volume

16

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

985-994

1 reference

24 December 2017

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Immunotherapy for nonmelanoma skin cancer: does it have a future?

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Nonmelanoma skin cancer

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Cytokine-based therapy and biochemotherapy for advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Melanoma immunology: past, present and future.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

A review of recent findings involving interleukin-2-based cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Tumor-driven evolution of immunosuppressive networks during malignant progression

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Immune monitoring of T-cell responses in cancer vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Human T cell responses against melanoma

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Treatment of oligometastases after successful immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

The innate immune response to adenovirus vectors

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.32

7 January 2021

Identifiers

DOI

10.1038/MT.2008.32

1 reference

24 December 2017

PubMed ID

18388930

1 reference

24 December 2017